Home > Cardiology > AHA 2020 > Letter from the Editor

Letter from the Editor

Prof. Marc Bonaca, University of Colorado, USA
AHA 2020
Dear Colleagues,

We wish you well during this difficult time and we welcome you to review Medicom’s summary of the American Heart Association’s Virtual Scientific Sessions 2020. As we have come to expect this year, this rich exchange of science and clinical updates was conducted through an interactive virtual platform. In the following pages, you will find a summary of the cutting edge and late-breaking science that was presented including new updates in COVID 19, new results of a polypill approach, advances in heart failure, advances in vascular medicine, and many clinical trial results and key sub-analyses.

A key focus of this year’s sessions were efforts to focus on groups and patients who are often underrepresented in cardiovascular research, including women, children, ethnic minorities, and the elderly, and you will find summaries in this report. Disparities in healthcare and research remain a serious problem globally and we support the commitment to work as a community to achieve greater equity.

We hope you will find the content to be clear, succinct, insightful and interesting. As always, all content undergoes a rigorous peer-review process to ensure balance and accuracy. Thank you for reading Medicom’s summary, thank you for all you do to help others and further scientific knowledge, and we hope you and your families stay safe and healthy.



Marc Bonaca



Marc P. Bonaca, MD, MPH, is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health at the University of Colorado Anschutz Medical Campus. He is the Director of Vascular Research and an Associate Professor of Medicine at the University of Colorado School of Medicine and the inaugural holder of the William R. Hiatt Endowed Chair in Cardiovascular Research.

Dr Bonaca earned his medical degree from the University of Connecticut School of Medicine and his Masters in Public Health at Harvard University. He served as a Medical House Officer at Brigham and Women’s Hospital and Harvard Medical School. After completion of his training he joined the faculty of the Cardiovascular Division and Vascular Medicine section of Brigham and Women’s Hospital and Harvard Medical School and became an Investigator at the TIMI Study Group.

Dr Bonaca’s research focus is on ischemic risk in patients with atherosclerotic vascular disease, risk prediction, and risk modification through the use of pharmacologic and biologic therapies. His key areas of interest include patients with peripheral artery disease, polyvascular disease and diabetes with a focus on the breadth of risk including ischemic limb outcomes, microvascular complications and major adverse cardiovascular events.

Conflict of Interest Statement:

Grant support to BWH from AstraZeneca, MedImmune, Merck, PfizerGrant support to CPC from Amgen, AstraZeneca, Bayer, Janssen, NovoNordisk, Sanofi


Posted on